GlassScriptPhysician profile
Venkat Nutalapati
NPI 1114367869
$3,699.44
in general payments reported to CMS, 2019-2025
14 companies · $455 in 2025
The $455 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $266 · 2020: $1,681 · 2021: $701 · 2022: $99.64 · 2023: $430 · 2024: $67.24 · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $952.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $951.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cook Medical LLC | $1,666.67 | 2020 | |
| Abbvie INC. | $535.90 | 2023-2025 | |
| Medtronic, INC. | $296.60 | 2021 | |
| Janssen Scientific Affairs, LLC | $241.76 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $199.28 | 2021-2022 | |
| Janssen Biotech, INC. | $156.35 | 2025 | Tremfya |
| Boston Scientific Corporation | $144.93 | 2019-2025 | General - Polypectomy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $125.60 | 2021 | |
| Gilead Sciences, INC. | $125.00 | 2023 | Epclusa |
| Daiichi Sankyo INC. | $118.57 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.37 | 2020-2025 | Entyvio |
| Ardelyx, INC. | $19.74 | 2025 | Ibsrela |
| Braintree Laboratories, INC. | $18.27 | 2025 | Sutab, Suflave |
| Regeneron Healthcare Solutions, INC. | $17.40 | 2025 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Venkat Nutalapati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.